Marshall Wace
PJP icon

Marshall Wace’s Invesco Pharmaceuticals ETF PJP Stock Holding History

Marshall Wace’s Portfolio PJP Stock Details PJP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-922
Closed -$75K – 3865
2021
Q4 		$75K Buy
+922
New +$72.9K ﹤0.01% 3459

Other funds holding PJP

PAM
Peak Asset Management Louisville, Colorado $680M AUM 22.27% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Marshall Wace's PJP Position: Q1 2022 in Review

Marshall Wace sold out of Invesco Pharmaceuticals ETF (PJP) in Q1 2022, closing a stake of 922 shares — an estimated $75K sold.

Marshall Wace first reported a position in PJP in Q4 2021 and held it in 1 quarter. The position peaked at $75K in Q4 2021. 88 funds tracked by Wall St. Rank hold PJP as of Q1 2022.

  • Marshall Wace reported no remaining Invesco Pharmaceuticals ETF position as of Q1 2022 after selling out during the quarter.
  • Marshall Wace sold 922 Invesco Pharmaceuticals ETF shares in Q1 2022, an estimated $75K.
  • Marshall Wace first reported a position in Invesco Pharmaceuticals ETF in Q4 2021 and held it in 1 quarter.
  • Marshall Wace's Invesco Pharmaceuticals ETF position peaked at $75K in Q4 2021.
  • 88 funds tracked by Wall St. Rank held Invesco Pharmaceuticals ETF as of Q1 2022.

Based on Marshall Wace's 13F filing for Q1 2022, filed 16 May 2022.